# Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

> **NCT04681911** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 71 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Inetetamab
- **DRUG:** Pyrotinib
- **DRUG:** Capecitabine
- **DRUG:** Gemcitabine
- **DRUG:** Vinorelbine
- **DRUG:** Carboplatin
- **DRUG:** Albumin paclitaxel
- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT04681911
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-09
- **Primary completion:** 2023-09-09
- **Final completion:** 2024-09-09
- **Target enrollment:** 71 (ESTIMATED)
- **Last updated:** 2020-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04681911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04681911, "Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04681911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*